Abstract
AbstractAlthough immunoglobulin VH mutation status (IgVH MS) is prognostic in patients with chronic lymphocytic leukemia (CLL) who are treated with alkylating agents or single-agent fludarabine, its significance in the era of chemoimmunotherapy is not known. We determined the IgVH somatic mutation status (MS) in 177 patients enrolled in a phase 2 study of fludarabine, cyclophosphamide, and rituximab (FCR) and in 127 patients treated with subsequent chemoimmunotherapy protocols. IgVH MS did not impact significantly on the complete remission (CR) rate of patients receiving FCR or related regimens. However, CR duration was significantly shorter in patients with CLL that used unmutated IgVH than those whose CLL used mutated IgVH (TTP 47% vs 82% at 6 years, P < .001). In a multivariate model considering all baseline characteristics, IgVH MS emerged as the only determinant of remission duration (hazard ratio 3.8, P < .001). Our results suggest that postremission interventions should be targeted toward patients with unmutated IgVH status.
Highlights
Used mutated IgVH (TTP 47% vs 82% at 6 years, P < .001)
immunoglobulin VH mutation status (IgVH mutation status (MS)) was available in 177 FCR patients, with 59% having UM-chronic lymphocytic leukemia (CLL) and 41% having M-CLL (Table 1)
Clinical data from 127 patients treated on protocols subsequent to FCR were pooled (Table 1) to examine for differences between patients with UM-CLL (69%) and M-CLL (31%)
Summary
Relevance of the Immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Patients with cells that used an unmutated IgVH gene (UM-CLL) had inferior rates of survival compared with those that used a mutated IgVH gene (M-CLL).[1,2] it was unclear whether this difference was because of inferior treatment response, increased risk of relapse from remission, or both.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
